MedPath
HSA Product

MEFRIL-250 CAPSULE 250 mg

Product approved by Health Sciences Authority (SG)

Basic Information

MEFRIL-250 CAPSULE 250 mg

CAPSULE

Regulatory Information

SIN10125P

October 2, 1998

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XM01AG01

Company Information

MICRO LABS LTD

NAINA MOHAMED & SONS PRIVATE LIMITED

NAINA MOHAMED & SONS PRIVATE LIMITED

Active Ingredients

MEFENAMIC ACID

Strength: 250 mg

Detailed Information

Contraindications

**CONTRAINDICATIONS:** - Hypersensitivity to the active substance or any of the excipients - Inflammatory bowel disease. - History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy. - Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). - Severe heart failure, hepatic failure and renal failure. - History of hypersensitivity reaction to other NSAIDs. - During the last trimester of pregnancy. - Treatment of pain after coronary artery bypass graft (CABG) surgery.

Indication Information

**INDICATIONS AND USES:** Mefenamic acid capsules is used to relieve various types of pain such as: headache; body aches, rheumatoid arthritis, osteoarthritis; muscle and joint pains; toothache; sprains; painful menstruation (dysmenorrhea and menorrhagia); trauma-related pains.

© Copyright 2025. All Rights Reserved by MedPath